An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics has announced the pricing of a $13.8 million public offering, selling 3,066,666 units at $4.50 each. The proceeds will be used for working capital, general corporate purposes, and advancing business objectives. The offering is expected to close on April 28, 2025, and the warrants included in the units will commence trading on Nasdaq under the symbol ‘BCTXZ’.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics’ overall score is primarily weighed down by its financial instability, characterized by no revenue and consistent losses. While the technical analysis provides some neutral insights, the valuation concerns due to lack of profitability and dividend yield further impact the score. However, promising corporate developments in cancer treatment provide a potential upside, although significant financial risks persist.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
YTD Price Performance: -37.12%
Average Trading Volume: 15,009
Technical Sentiment Signal: Buy
Current Market Cap: C$26.41M
For a thorough assessment of BCT stock, go to TipRanks’ Stock Analysis page.